🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. NFC-1

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  2. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  3. NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo

    Pierre Fabre Medicament

    Cessation of smoking

    phase 3 small molecule active

    1 trial

  4. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

  5. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  6. NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Novartis Pharmaceuticals

    Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

    phase 3 small molecule active

    1 trial

  7. NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir

    Pfizer Australia Pty Ltd

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  8. NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL

    Amgen

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  9. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. NKTR-102

    Nektar Therapeutics UK Limited

    Metastasis

    phase 3 small molecule completed

    1 trial

  11. NKTR-102

    Nektar Therapeutics UK Limited

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  12. NKTR-118

    AstraZeneca

    Opioid-Induced Constipation

    phase 3 small molecule terminated

    1 trial

  13. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  14. NKTR-214

    Bristol-Myers Squibb

    Melanoma

    phase 3 mab completed

    1 trial

  15. NKTR-214

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab completed

    1 trial

  16. NKTR-255 at 1.5 µg/kg

    Nektar Therapeutics UK Limited

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  17. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  18. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  19. NNC0487-0111

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  20. NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  21. NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  22. NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  23. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  24. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources